IRIS
CIARDIELLO, Fortunato
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 33.447
NA - Nord America 14.553
AS - Asia 12.308
SA - Sud America 2.280
AF - Africa 140
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 18
Totale 62.774
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 21.585
US - Stati Uniti d'America 14.340
SG - Singapore 4.632
IE - Irlanda 3.513
CN - Cina 2.684
HK - Hong Kong 2.348
BR - Brasile 1.975
UA - Ucraina 1.723
GB - Regno Unito 1.540
IT - Italia 1.502
DE - Germania 1.237
VN - Vietnam 639
FR - Francia 605
KR - Corea 601
FI - Finlandia 536
SE - Svezia 467
IN - India 380
GR - Grecia 351
TR - Turchia 325
JP - Giappone 230
AR - Argentina 116
CA - Canada 115
AT - Austria 86
BD - Bangladesh 77
ID - Indonesia 76
PK - Pakistan 75
NL - Olanda 65
MX - Messico 62
EC - Ecuador 60
IQ - Iraq 55
PL - Polonia 51
BE - Belgio 46
ES - Italia 36
ZA - Sudafrica 34
CO - Colombia 33
CZ - Repubblica Ceca 28
MA - Marocco 28
PY - Paraguay 25
CL - Cile 22
VE - Venezuela 21
AU - Australia 19
SA - Arabia Saudita 18
AZ - Azerbaigian 16
EG - Egitto 16
IL - Israele 16
AE - Emirati Arabi Uniti 15
EU - Europa 15
IR - Iran 15
JO - Giordania 15
UZ - Uzbekistan 14
KE - Kenya 12
DZ - Algeria 11
PE - Perù 11
CH - Svizzera 10
DO - Repubblica Dominicana 10
TN - Tunisia 10
AL - Albania 9
BO - Bolivia 9
MY - Malesia 9
HU - Ungheria 8
KG - Kirghizistan 8
NP - Nepal 8
NZ - Nuova Zelanda 8
LB - Libano 7
LT - Lituania 7
TW - Taiwan 7
HR - Croazia 6
SN - Senegal 6
CG - Congo 5
CR - Costa Rica 5
HN - Honduras 5
KZ - Kazakistan 5
RO - Romania 5
TT - Trinidad e Tobago 5
UY - Uruguay 5
AO - Angola 4
BH - Bahrain 4
BY - Bielorussia 4
ET - Etiopia 4
JM - Giamaica 4
LV - Lettonia 4
MK - Macedonia 4
RS - Serbia 4
GY - Guiana 3
MM - Myanmar 3
OM - Oman 3
PH - Filippine 3
PT - Portogallo 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
BB - Barbados 2
BG - Bulgaria 2
EE - Estonia 2
GA - Gabon 2
GI - Gibilterra 2
KW - Kuwait 2
LK - Sri Lanka 2
ML - Mali 2
NG - Nigeria 2
NO - Norvegia 2
Totale 62.746
Salva come PNG Salva come JPEG
Città #
Moscow 7.590
Dublin 3.495
Jacksonville 2.638
Hong Kong 2.341
Santa Clara 1.844
Singapore 1.703
Chandler 1.692
Wilmington 694
Seoul 575
Princeton 557
Chicago 549
Medford 493
Hefei 451
Ashburn 377
New York 336
Falls Church 334
Boardman 311
San Mateo 292
Bengaluru 289
Beijing 286
Dallas 261
Roxbury 257
Ann Arbor 250
Naples 234
Bremen 231
Ho Chi Minh City 227
Munich 211
The Dalles 209
Caserta 184
São Paulo 167
Woodbridge 161
Hanoi 125
Cambridge 124
Los Angeles 122
Des Moines 118
Nanjing 95
Nuremberg 83
Houston 67
Jinan 64
Rio de Janeiro 60
Elora 59
Turku 57
Mountain View 52
Napoli 50
Belo Horizonte 48
Vienna 45
Shanghai 44
Dong Ket 42
Norwalk 42
Brussels 40
Helsinki 40
Düsseldorf 39
Tianjin 39
Guangzhou 35
Nanchang 35
Aversa 34
Brasília 34
Lappeenranta 34
Curitiba 33
Falkenstein 31
Amsterdam 28
Milan 28
Campinas 27
Shenyang 27
Tokyo 27
Haiphong 26
Kraków 26
Changsha 25
Columbus 25
Da Nang 24
Jakarta 24
Quito 24
Brno 23
Brooklyn 23
Goiânia 23
Guarulhos 23
London 23
Auburn Hills 22
Porto Alegre 22
Ribeirão Preto 22
Venice 22
Salvador 21
San Francisco 21
Istanbul 20
Redwood City 20
Rome 20
Warsaw 18
Zhengzhou 18
Boston 17
Council Bluffs 17
Guayaquil 17
Kunming 17
Taiyuan 17
Dhaka 16
Ercolano 16
Hangzhou 16
Ninh Bình 16
Ottawa 16
Amman 15
Baghdad 15
Totale 31.777
Salva come PNG Salva come JPEG
Nome #
Epigenetic mechanisms underlying prostate cancer radioresistance 1.415
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 221
ONCOLOGIA MEDICA 197
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 197
Beyond N staging in colorectal cancer: Current approaches and future perspectives 196
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis 196
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 192
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. 191
A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non-Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial. 186
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 173
AXL is an oncotarget in human colorectal cancer 172
A trimodality, four-step treatment including chemotherapy, pleurectomy/decortication and radiotherapy in early-stage malignant pleural mesothelioma: A single-institution retrospective case series study 171
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 168
Adjuvant chemoradiotherapy in patients with stage III-IV radically resected gastric cancer: a pilot study 165
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 165
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 164
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 164
CBX2 shapes chromatin accessibility promoting AML via p38 MAPK signaling pathway 163
Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma—a pilot study. Curr Oncol 21, 3, june 2014 125-133 163
Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells 162
A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells 161
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 161
Chronic inflammation and oxidative stress in human carcinogenesis 159
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 158
Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: A propensity score-matched analysis 158
Expression of c-MET in Estrogen Receptor Positive and HER2 Negative Resected Breast Cancer Correlated with a Poor Prognosis 157
A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics 157
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients 157
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 157
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC? 157
Clinical management of advanced gastric cancer: Role of new molecular drugs. 156
A possible connective tissue primary lymphoepithelioma-like carcinoma (LELC). 156
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 156
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 154
Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study) 150
Immunotherapy for head and neck cancer: Present and future 149
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 149
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 147
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. 146
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 146
A preliminary study for quantitative assessment with HFUS (High-frequency ultrasound) of nodular skin melanoma breslow thickness in adults before surgery: Interdisciplinary team experience 146
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 145
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 145
Modified blade: an interventional option in rigid bronchoscopy for non-resectable benign tracheal stenosis 144
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 144
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. 144
Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer 144
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 144
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 144
Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials 143
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 143
Conversion chemotherapy followed by epatic resection in colorectal cancer with initially unresectable liver-limited metastases 142
Intraoperative ultrasound: "Alternative eye" in lymph nodal dissection in non-small cell lung cancer 141
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 140
Prediction of preoperative intrathoracic adhesions for ipsilateral reoperations: sliding lung sign 139
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer 139
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 138
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 138
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 138
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 137
Treatment of gastric cancer. 136
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 136
CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial 135
1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. 135
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy 135
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials 135
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 134
Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics 134
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 134
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 134
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 134
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial 133
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations 133
Clinical management of metastatic colorectal cancer in the era of precision medicine 133
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 132
Antiangiogenic drugs in non small cell lung cancer treatment 132
8-chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo 132
AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma 131
Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis 131
Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota 131
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 130
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor 130
Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer 130
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 130
8-chloro-cAMP enhances the growth inhibitory effect of cytotoxic drugs in humancolon cancer cells 129
Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass 128
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 128
Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer 128
A meta-analysis on the interactionbetween HER-2 expression and response to endocrine treatment in advanced breastcancer 127
Farmacogenomica e cancro colorettale 127
8-Chloro-cyclic AMP inhibits autocrine and angiogenic growth factor production in human colorectal and breast cancer 127
TGF-β Modulated Pathways in Colorectal Cancer: New Potential Therapeutic Opportunities 126
Intraoperative lung ultrasound improves subcentimetric pulmonary nodule localization during VATS: Results of a retrospective analysis 126
A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer 126
Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs 126
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 126
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors 125
TRASTUZUMAB RESISTANCE IN BREAST CANCER 125
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 125
Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines 124
Totale 15.963
Salva come PNG Salva come JPEG
Categoria #
all - tutte 220.846
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 220.846
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.151 0 0 0 0 0 42 536 414 69 504 426 160
2021/20224.183 400 171 288 158 1.304 73 83 114 159 165 300 968
2022/20237.055 796 176 392 603 674 567 31 366 3.135 44 136 135
2023/20242.895 245 89 130 249 998 337 61 61 48 27 199 451
2024/20258.974 97 169 120 305 1.245 1.098 894 846 1.204 1.773 650 573
2025/202630.641 1.423 1.752 2.045 1.998 2.916 20.507 0 0 0 0 0 0
Totale 63.780